{"hands_on_practices": [{"introduction": "A patient presenting with an acute neurovisceral crisis requires a rapid and logical diagnostic approach. This practice challenges you to distinguish between a rare genetic porphyria and an acquired toxin exposure that present with nearly identical clinical and biochemical features. By constructing a diagnostic algorithm, you will practice using key laboratory markers like urinary $\\delta$-aminolevulinic acid (ALA), porphobilinogen (PBG), and blood lead levels to systematically arrive at the correct diagnosis, a fundamental skill in internal medicine.", "problem": "A $38$-year-old battery plant technician presents with $3$ days of severe episodic abdominal pain, proximal muscle weakness, constipation, and new-onset anxiety. Vital signs are stable. The neurologic examination shows mild wrist extensor weakness without sensory loss. Serum sodium is mildly decreased. There is no rash or photosensitivity. You suspect an acute hepatic porphyria but note the occupational exposure to lead. You must design a stepwise diagnostic approach that uses urine delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), together with a blood lead level, to discriminate genetic ALA dehydratase deficiency porphyria (ALAD porphyria, ALAD-P) from acquired lead toxicity.\n\nUse the following foundational facts as your starting point: in the heme biosynthetic pathway, delta-aminolevulinic acid dehydratase (ALAD) catalyzes the conversion of ALA to PBG in the cytosol; in acute intermittent porphyria (AIP) and other acute hepatic porphyrias with a block at or distal to PBG deaminase, urine PBG is elevated during attacks; in ALAD-P, the enzymatic block is proximal (at ALAD), leading to elevated ALA with normal or near-normal PBG; lead inhibits ALAD and ferrochelatase, typically causing elevated ALA with normal PBG and an elevated blood lead level.\n\nWhich of the following algorithms most appropriately distinguishes genetic ALAD-P from acquired lead toxicity, while remaining consistent with these principles and with urgent testing applicable during an attack?\n\nA. Step $1$: During symptoms, obtain a spot urine ALA and PBG. If urine PBG is elevated, classify as an acute hepatic porphyria other than ALAD-P and manage accordingly. If urine ALA is elevated with normal PBG, measure a blood lead concentration. An elevated blood lead indicates acquired lead toxicity; a normal blood lead indicates likely ALAD-P. Confirmations may include low red blood cell (RBC) ALAD activity or ALAD gene testing for ALAD-P, and elevated RBC zinc protoporphyrin for lead. In infants or young children with isolated ALA elevation, exclude hereditary tyrosinemia type $1$ by urine succinylacetone.\n\nB. Step $1$: Measure a blood lead concentration. If it is normal, diagnose ALAD-P; if it is elevated, measure urine ALA and PBG. If both ALA and PBG are elevated, confirm ALAD-P; if only ALA is elevated with normal PBG, diagnose acute intermittent porphyria (AIP).\n\nC. Step $1$: Obtain fecal porphyrins. If coproporphyrin is increased, diagnose lead toxicity; if protoporphyrin is increased, diagnose ALAD-P. Blood lead measurement is unnecessary when fecal porphyrins are abnormal. Urine ALA and PBG are reserved for equivocal cases.\n\nD. Step $1$: During symptoms, measure urine PBG only. If PBG is normal, exclude porphyria. If PBG is elevated, measure blood lead; a normal blood lead confirms lead toxicity, and an elevated blood lead confirms ALAD-P. Urine ALA testing is not necessary because PBG is the key discriminator.\n\nE. Step $1$: During symptoms, measure urine ALA and PBG. If ALA is elevated with normal PBG, treat empirically with hemin and avoid measuring blood lead because hemin will reduce ALA in both ALAD-P and lead poisoning, making subsequent interpretation difficult; perform porphyrin fractionation later for definitive diagnosis.", "solution": "The user has provided a clinical problem that requires the construction of a diagnostic algorithm to differentiate between two specific medical conditions. I will first validate the problem statement and then proceed to a step-by-step derivation of the solution and evaluation of the given options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Clinical Presentation:** A $38$-year-old male battery plant technician with a $3$-day history of severe episodic abdominal pain, proximal muscle weakness, constipation, and new-onset anxiety.\n*   **Physical Examination and Labs:** Stable vital signs, mild wrist extensor weakness without sensory loss, mildly decreased serum sodium. No rash or photosensitivity.\n*   **Context:** Occupational exposure to lead is noted. The differential diagnosis is between an acute hepatic porphyria and acquired lead toxicity.\n*   **Objective:** Design a stepwise diagnostic approach using urine delta-aminolevulinic acid (ALA, $\\delta$-aminolevulinic acid), urine porphobilinogen (PBG), and blood lead level to distinguish genetic ALA dehydratase deficiency porphyria (ALAD-P) from acquired lead toxicity.\n*   **Provided Foundational Principles:**\n    1.  The enzyme delta-aminolevulinic acid dehydratase (ALAD) catalyzes the conversion of ALA to PBG.\n    2.  In acute intermittent porphyria (AIP) and other acute hepatic porphyrias with an enzymatic block at or distal to PBG deaminase, urine PBG is elevated during attacks.\n    3.  In ALAD-P, the enzymatic block at ALAD leads to elevated ALA with normal or near-normal PBG.\n    4.  Lead inhibits the enzymes ALAD and ferrochelatase, typically causing elevated ALA with normal PBG, accompanied by an elevated blood lead level.\n\n**Step 2: Validate Using Extracted Givens**\n\n*   **Scientific Groundedness:** The problem statement is scientifically and medically sound. The clinical presentation is a classic neurovisceral syndrome, characteristic of both acute porphyria attacks and lead poisoning (plumbism). The biochemical facts provided about the heme synthesis pathway, the specific enzyme defects in ALAD-P and AIP, and the inhibitory effects of lead on ALAD and ferrochelatase are all well-established principles in biochemistry and internal medicine. The differential diagnosis is clinically realistic and important.\n*   **Well-Posedness:** The problem is well-posed. It asks for a specific diagnostic algorithm to differentiate between two conditions with a nearly identical biochemical profile (elevated ALA, normal PBG). The tools provided (urine ALA, urine PBG, blood lead) are the standard and necessary tests to resolve this specific clinical question. A single, logical diagnostic pathway can be constructed.\n*   **Objectivity:** The problem is stated in objective, clinical language, free of bias or subjective claims.\n\n**Step 3: Verdict and Action**\n\nThe problem is **valid**. The provided information is self-contained, scientifically accurate, and allows for the construction of a logical, definitive solution. I will now proceed to derive the correct diagnostic algorithm and evaluate the options.\n\n### Derivation of the Correct Diagnostic Algorithm\n\nThe patient presents with an acute neurovisceral attack. The primary goal is to urgently establish a diagnosis to guide therapy. The differential includes several acute hepatic porphyrias (AIP, Variegate Porphyria, Hereditary Coproporphyria), the very rare ALAD-P, and lead toxicity, which mimics ALAD-P biochemically.\n\n1.  **Initial Screening:** The most crucial first step during an acute attack is to measure urinary porphyrin precursors. The single most important test to rapidly diagnose or exclude the most common acute hepatic porphyrias (AIP, VP, HCP) is a spot urine PBG.\n    *   If **urine PBG is significantly elevated**, the diagnosis is an acute hepatic porphyria such as AIP. This finding makes ALAD-P and lead poisoning as the cause of this specific biochemical result highly unlikely, as the enzymatic block in those conditions is proximal to PBG synthesis.\n    *   If **urine PBG is normal or near-normal**, the common acute porphyrias are effectively ruled out as the cause of the attack. At this point, the suspicion shifts to conditions causing a pre-PBG block.\n\n2.  **Characterizing the Pre-PBG Block:** Given a normal PBG and high clinical suspicion, the next step is to confirm the accumulation of the precursor proximal to PBG, which is ALA. Therefore, measurement of urine ALA is essential. The expected finding in this scenario (based on the symptoms and the now-narrowed differential) would be **elevated urine ALA**. The combination of elevated ALA and normal PBG is the hallmark of ALAD inhibition.\n\n3.  **Differentiating Intrinsic vs. Extrinsic ALAD Inhibition:** The biochemical profile of `elevated ALA + normal PBG` is shared by genetic ALAD-P and acquired lead toxicity. The clinical history of a battery plant technician strongly suggests the possibility of lead exposure. The most direct and definitive way to distinguish between these two etiologies is to measure the concentration of the suspected toxin.\n    *   Measure the **blood lead level**.\n    *   An **elevated blood lead level** confirms the diagnosis of acquired lead toxicity.\n    *   A **normal blood lead level** in the face of this biochemical profile makes genetic ALAD-P the highly probable diagnosis.\n\n4.  **Confirmatory Testing:** While the above steps are sufficient for initial diagnosis and management, definitive confirmation is often pursued.\n    *   For a presumptive diagnosis of **ALAD-P** (based on normal blood lead), one would confirm by demonstrating markedly reduced ALAD enzyme activity in red blood cells (RBCs) and/or by identifying pathogenic mutations in the *ALAD* gene.\n    *   For a diagnosis of **lead toxicity**, a useful confirmatory finding is an elevated RBC zinc protoporphyrin (ZPP). Lead's inhibition of ferrochelatase (which inserts iron into protoporphyrin) leads to the alternative insertion of zinc, forming ZPP.\n\nThis logically derived sequence represents the optimal and standard-of-care approach to this clinical problem.\n\n### Option-by-Option Analysis\n\n**A. Step $1$: During symptoms, obtain a spot urine ALA and PBG. If urine PBG is elevated, classify as an acute hepatic porphyria other than ALAD-P and manage accordingly. If urine ALA is elevated with normal PBG, measure a blood lead concentration. An elevated blood lead indicates acquired lead toxicity; a normal blood lead indicates likely ALAD-P. Confirmations may include low red blood cell (RBC) ALAD activity or ALAD gene testing for ALAD-P, and elevated RBC zinc protoporphyrin for lead. In infants or young children with isolated ALA elevation, exclude hereditary tyrosinemia type $1$ by urine succinylacetone.**\n\nThis option perfectly matches the derived algorithm. It begins with the correct initial screen (urine ALA and PBG), correctly interprets an elevated PBG, correctly follows the path for normal PBG and elevated ALA, uses the blood lead level as the key differentiator, and correctly lists the appropriate confirmatory tests. The inclusion of the differential diagnosis for infants (hereditary tyrosinemia type $1$) demonstrates a comprehensive and correct understanding of the topic.\n\n*   **Verdict:** **Correct**\n\n**B. Step $1$: Measure a blood lead concentration. If it is normal, diagnose ALAD-P; if it is elevated, measure urine ALA and PBG. If both ALA and PBG are elevated, confirm ALAD-P; if only ALA is elevated with normal PBG, diagnose acute intermittent porphyria (AIP).**\n\nThis option is flawed in multiple ways. First, starting with a blood lead level is inefficient; a normal lead level does not rule out the more common acute porphyrias like AIP. Second, diagnosing ALAD-P based solely on a normal lead level is a leap of logic that prematurely dismisses other porphyrias. Third, it contains fundamental biochemical errors: it states that elevated ALA and PBG confirm ALAD-P, which contradicts the fact that in ALAD-P, PBG is normal. It also states that isolated ALA elevation diagnoses AIP, which is incorrect; AIP is characterized by elevated PBG.\n\n*   **Verdict:** **Incorrect**\n\n**C. Step $1$: Obtain fecal porphyrins. If coproporphyrin is increased, diagnose lead toxicity; if protoporphyrin is increased, diagnose ALAD-P. Blood lead measurement is unnecessary when fecal porphyrins are abnormal. Urine ALA and PBG are reserved for equivocal cases.**\n\nThis option proposes an incorrect initial test. Fecal porphyrins are not the primary diagnostic tool for an acute neurovisceral attack; urinary PBG and ALA are. The diagnostic criteria cited are oversimplified and potentially inaccurate. Most critically, the statement that blood lead measurement is unnecessary is dangerous and medically incorrect. If lead toxicity is suspected, measuring blood lead is the definitive diagnostic standard.\n\n*   **Verdict:** **Incorrect**\n\n**D. Step $1$: During symptoms, measure urine PBG only. If PBG is normal, exclude porphyria. If PBG is elevated, measure blood lead; a normal blood lead confirms lead toxicity, and an elevated blood lead confirms ALAD-P. Urine ALA testing is not necessary because PBG is the key discriminator.**\n\nThis option contains critical errors. Stating that a normal PBG \"excludes porphyria\" is false; it fails to account for ALAD-P. The logic following an elevated PBG is completely backward and biochemically nonsensical. An elevated PBG points to AIP/VP/HCP, not lead toxicity or ALAD-P. The assertion that urine ALA is not necessary is also false, as it is essential for identifying ALAD inhibition when PBG is normal.\n\n*   **Verdict:** **Incorrect**\n\n**E. Step $1$: During symptoms, measure urine ALA and PBG. If ALA is elevated with normal PBG, treat empirically with hemin and avoid measuring blood lead because hemin will reduce ALA in both ALAD-P and lead poisoning, making subsequent interpretation difficult; perform porphyrin fractionation later for definitive diagnosis.**\n\nThis option starts correctly but then gives flawed advice. While empirical treatment with hemin is a reasonable therapeutic consideration as it will lower ALA levels in both conditions, the recommendation to *avoid* measuring blood lead is a serious error. Hemin has no effect on the blood lead concentration itself. Delaying the definitive diagnosis of lead poisoning, which requires specific management including source removal and possible chelation therapy, is inappropriate. The definitive test to distinguish the two conditions (blood lead) should be performed urgently and is not compromised by hemin administration.\n\n*   **Verdict:** **Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4788459"}, {"introduction": "Once an acute hepatic porphyria is diagnosed, prompt treatment is critical to halt the neurotoxic process. This exercise focuses on the practical application of administering intravenous hemin, the cornerstone of acute therapy. You will perform a weight-based dose calculation and devise a safe infusion plan, skills that directly translate to inpatient care and highlight the importance of not just *what* to prescribe, but *how* to administer it safely to minimize adverse effects.", "problem": "A patient with an acute hepatic porphyria is admitted for treatment to suppress hepatic delta-aminolevulinic acid synthase 1 (ALAS1) overexpression and reduce accumulation of neurotoxic precursors such as 5-aminolevulinic acid (ALA) and porphobilinogen (PBG). The patient weighs $70\\ \\mathrm{kg}$. The attending physician prescribes hemin at $3.5\\ \\mathrm{mg/kg/day}$ for $4$ consecutive days. In practice, hemin can irritate peripheral veins; to minimize the risk of phlebitis, infusion strategies commonly include using a central venous catheter (CVC), dilution in human albumin solution, and avoiding rapid bolus administration.\n\nUsing only first principles appropriate to dose calculation in internal medicine and a medically sound rationale for infusion scheduling, compute the patient’s total cumulative hemin dose over the $4$-day course. Then, propose an infusion schedule that minimizes phlebitis risk, explicitly stating at least one measure related to access, dilution, and rate that is consistent with clinical practice for hemin. Your numerical answer will be graded solely on the total cumulative dose; the schedule will be evaluated qualitatively in the explanation.\n\nExpress the total cumulative dose in grams, and round your final numeric answer to three significant figures. Do not include units in your final boxed answer; however, use grams (g) in your working and reasoning where applicable.", "solution": "The problem statement has been validated and is deemed sound. It is scientifically grounded in the principles of internal medicine and pharmacology, well-posed with sufficient information for a unique numerical solution, and objective in its presentation. The clinical context, including the pathophysiology of acute hepatic porphyria, the therapeutic mechanism of hemin, standard dosing regimens, and adverse effect management, is accurate.\n\nThe primary task is to compute the total cumulative dose of hemin for a patient and propose a safe infusion schedule.\n\nFirst, we identify the given parameters:\n-   Patient weight, $W = 70\\ \\mathrm{kg}$\n-   Prescribed daily dosage rate, $d = 3.5\\ \\mathrm{mg/kg/day}$\n-   Duration of treatment, $t = 4\\ \\mathrm{days}$\n\nThe calculation proceeds in two steps: first, determining the daily dose, and second, calculating the total dose over the entire treatment course.\n\nStep 1: Calculate the patient's daily dose of hemin, $D_{daily}$.\nThe daily dose is the product of the patient's weight and the prescribed dosage rate.\n$$D_{daily} = W \\times d$$\nSubstituting the given values:\n$$D_{daily} = 70\\ \\mathrm{kg} \\times 3.5\\ \\frac{\\mathrm{mg}}{\\mathrm{kg} \\cdot \\mathrm{day}} = 245\\ \\frac{\\mathrm{mg}}{\\mathrm{day}}$$\nThus, the patient requires a dose of $245\\ \\mathrm{mg}$ of hemin each day.\n\nStep 2: Calculate the total cumulative dose, $D_{total}$, over the treatment period.\nThe total dose is the daily dose multiplied by the number of days of treatment.\n$$D_{total} = D_{daily} \\times t$$\nSubstituting the calculated daily dose and the given duration:\n$$D_{total} = 245\\ \\frac{\\mathrm{mg}}{\\mathrm{day}} \\times 4\\ \\mathrm{days} = 980\\ \\mathrm{mg}$$\n\nStep 3: Convert the total dose to grams, as requested, and apply rounding.\nThe conversion factor between milligrams ($mg$) and grams ($g$) is $1000\\ \\mathrm{mg} = 1\\ \\mathrm{g}$.\n$$D_{total, g} = D_{total} \\times \\frac{1\\ \\mathrm{g}}{1000\\ \\mathrm{mg}}$$\n$$D_{total, g} = 980\\ \\mathrm{mg} \\times \\frac{1\\ \\mathrm{g}}{1000\\ \\mathrm{mg}} = 0.980\\ \\mathrm{g}$$\nThe problem requires the final answer to be rounded to three significant figures. The calculated value $0.980$ already has three significant figures (the digits $9$, $8$, and the trailing $0$ are all significant).\n\nIn addition to the calculation, the problem requires a proposal for an infusion schedule that minimizes the risk of phlebitis, consistent with clinical best practices for hemin administration. The daily dose of $245\\ \\mathrm{mg}$ will be administered once daily for $4$ consecutive days. Based on the principles outlined in the problem statement and established medical guidelines, the following schedule is proposed:\n\n1.  **Venous Access**: To avoid the significant risk of chemical phlebitis associated with peripheral venous administration of hemin, the infusion should be administered through a central venous catheter (CVC). This allows the medication to be delivered into a large-lumen, high-flow vessel (e.g., the superior vena cava), promoting rapid dilution and minimizing endothelial contact time and irritation.\n\n2.  **Dilution**: Hemin for injection is supplied as a lyophilized powder that must be reconstituted. After reconstitution, it is highly recommended to further dilute the dose in a stabilizing solution. The daily dose of $245\\ \\mathrm{mg}$ of hemin should be admixed into a volume of at least $100\\ \\mathrm{mL}$ of $25\\%$ Human Albumin solution. Albumin binds hemin, buffers its pH closer to physiological levels, and reduces its irritant properties. This is a critical step in preventing phlebitis.\n\n3.  **Rate of Infusion**: Rapid bolus injection must be strictly avoided. The prepared solution of hemin in albumin should be infused slowly over a controlled period. A standard and safe duration is between $60$ and $120$ minutes. Therefore, administering the infusion over a period of not less than $60$ minutes using an infusion pump for accuracy is recommended.\n\nIn summary, the schedule involves a once-daily infusion for $4$ days, with each $245\\ \\mathrm{mg}$ dose diluted in human albumin and administered slowly via a central line. This multi-faceted approach directly addresses the primary risk factors for hemin-induced phlebitis.", "answer": "$$\\boxed{0.980}$$", "id": "4788377"}, {"introduction": "Beyond the acute porphyrias, managing chronic forms like porphyria cutanea tarda (PCT) requires a different therapeutic strategy. This problem shifts focus to the management of PCT, where iron overload is a key pathophysiological driver. You will use serum ferritin as a proxy for total body iron stores to calculate the number of therapeutic phlebotomies needed, providing hands-on practice in quantifying and planning a long-term treatment course for the most common porphyria.", "problem": "A patient with porphyria cutanea tarda (PCT) presents for management of iron overload as part of internal medicine treatment to reduce hepatic iron-mediated inhibition of uroporphyrinogen decarboxylase (UROD) and excessive induction of delta-aminolevulinate synthase 1 (ALAS1). Serum ferritin is used as a clinically validated proxy for total body iron stores. Assume the following well-tested clinical approximations and facts: (i) serum ferritin in $\\mathrm{ng/mL}$ correlates proportionally with total body iron stores such that each $1\\ \\mathrm{ng/mL}$ of ferritin corresponds to approximately $10\\ \\mathrm{mg}$ of stored iron; (ii) each $500\\ \\mathrm{mL}$ therapeutic phlebotomy removes approximately $200\\ \\mathrm{mg}$ of iron; (iii) mobilization from storage is appropriate, such that reductions in ferritin track reductions in total iron stores without confounding inflammation.\n\nThe patient’s serum ferritin is currently $400\\ \\mathrm{ng/mL}$, and the therapeutic target to minimize cutaneous fragility and blistering while restoring UROD activity is $50\\ \\mathrm{ng/mL}$. Based on these assumptions, determine the minimal integer number of $500\\ \\mathrm{mL}$ phlebotomy sessions required to reach the target ferritin. Express your final answer as a single integer count (dimensionless). Do not include units in your final answer. If your intermediate computation produces a non-integer, report the smallest integer greater than or equal to that value.", "solution": "The problem is deemed valid as it is scientifically grounded in the established pathophysiology and clinical management of porphyria cutanea tarda (PCT), is well-posed with all necessary information provided, and is expressed in objective, precise language. The data and assumptions are consistent with standard clinical approximations.\n\nThe goal is to determine the minimum integer number of phlebotomy sessions required to reduce a patient's serum ferritin level from an initial value to a target value.\n\nLet $F_i$ be the initial serum ferritin level, and $F_t$ be the target serum ferritin level.\nThe given values are:\nInitial ferritin, $F_i = 400\\ \\mathrm{ng/mL}$.\nTarget ferritin, $F_t = 50\\ \\mathrm{ng/mL}$.\n\nFirst, we calculate the required total reduction in serum ferritin, denoted as $\\Delta F$.\n$$\n\\Delta F = F_i - F_t = 400\\ \\mathrm{ng/mL} - 50\\ \\mathrm{ng/mL} = 350\\ \\mathrm{ng/mL}\n$$\n\nThe problem states a proportional relationship between serum ferritin and total body iron stores. The conversion factor, let's call it $C$, is given as $1\\ \\mathrm{ng/mL}$ of ferritin corresponding to $10\\ \\mathrm{mg}$ of stored iron.\n$$\nC = \\frac{10\\ \\mathrm{mg\\ iron}}{1\\ \\mathrm{ng/mL\\ ferritin}}\n$$\n\nUsing this factor, we can calculate the total mass of iron, $\\Delta M_{Fe}$, that needs to be removed from the body to achieve the desired reduction in ferritin.\n$$\n\\Delta M_{Fe} = \\Delta F \\times C\n$$\n$$\n\\Delta M_{Fe} = 350\\ \\mathrm{ng/mL} \\times \\left( \\frac{10\\ \\mathrm{mg}}{1\\ \\mathrm{ng/mL}} \\right) = 3500\\ \\mathrm{mg}\n$$\n\nEach therapeutic phlebotomy session is stated to remove a specific amount of iron. Let $M_{phleb}$ be the mass of iron removed per session.\n$$\nM_{phleb} = 200\\ \\mathrm{mg}\n$$\n\nTo find the number of phlebotomy sessions, $N$, required to remove the total mass of iron $\\Delta M_{Fe}$, we divide the total mass by the mass removed per session.\n$$\nN = \\frac{\\Delta M_{Fe}}{M_{phleb}} = \\frac{3500\\ \\mathrm{mg}}{200\\ \\mathrm{mg}}\n$$\n$$\nN = \\frac{35}{2} = 17.5\n$$\n\nSince phlebotomy sessions are discrete events and it is not possible to perform a fraction of a session, we must determine the minimal integer number of sessions. To meet or exceed the required iron removal, we must round the calculated number of sessions up to the nearest whole number. This operation is mathematically represented by the ceiling function, $\\lceil \\cdot \\rceil$.\n$$\nN_{required} = \\lceil N \\rceil = \\lceil 17.5 \\rceil = 18\n$$\n\nTherefore, a minimum of $18$ phlebotomy sessions are required. Performing $17$ sessions would only remove $17 \\times 200\\ \\mathrm{mg} = 3400\\ \\mathrm{mg}$ of iron, which is insufficient to meet the target reduction of $3500\\ \\mathrm{mg}$. The $18$-th session is necessary to ensure the therapeutic goal is reached.", "answer": "$$\\boxed{18}$$", "id": "4788466"}]}